Alcon AG · SIX:ALC
Alcon — Q3 2026 Earnings Presentation
31 slides from Alcon's earnings presentation, Nov 10, 2026
Slide 1: Third-Quarter 2026 Results
Third-Quarter 2026 Results November 10, 2026 1
Slide 2: Safe harbor
Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements
Slide 3: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 3
Slide 4: Q3 2026 Highlights
Q3 2026 Highlights • Sales of $2.7 billion, up 5% on a reported basis, or up 5% constant currency1 (cc), versus third- quarter 2025 • On track to deliver FY26 sales growth of 6% cc and double-digit core diluted EPS1 growth cc • Returned $748 million to shareholders through the first nine months • Ne
Slide 5: Select financial highlights
Select financial highlights Net sales Core operating margin1 3Q26 Sales of $2.7B, up 5% y/y on a reported basis; up 5% cc1 3Q26 Operating margin of 14.0%, up 120 3Q26 $2.7B 3Q26 21.8% basis points (bps) y/y; up 120 bps cc 3Q26 Core operating margin of 21.8%, up 3Q25 $2.6B 3Q25 20.2% 160 bps y/y; up
Slide 6: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 6
Slide 7: 9M 2026 Product mix
9M 2026 Product mix1 Vision Care $3.7B (45%) Surgical $4.5B (55%) Ocular health (40%) Implantables (29%) Dry eye products Monofocal IOLs Allergy eye drops Advanced technology IOLs Steroid eye drops Glaucoma implants Glaucoma eye drops Contact lens care Consumables (53%) $8.2 billion Dedicated consum
Slide 8: Q3 2026 Surgical
Q3 2026 Surgical Net Sales (USD) (CC)1 (USD $M) $1,420 $1,480 4% 4% • Implantables reflects strong performance by PanOptix Pro and growth in (2%) (2%) $422 international markets $432 + • Consumables reflects procedural growth, price increases, and Valeda consumables • Equipment growth reflects equip
Slide 9: Q3 2026 Vision Care
Q3 2026 Vision Care Net Sales (USD $M) (USD) (CC)1 $1,169 $1,237 6% 6% • Favorable mix of premium contact lenses as well as price increases, particularly in the U.S. + • Ocular health growth led by our portfolio of dry eye products, including Tryptyr and Systane $707 $737 4% 5% - • Declines in legac
Slide 10: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 10
Slide 11: Q3 2026 IFRS results
Q3 2026 IFRS results Worldwide net sales Operating margin Diluted EPS $2.7B 14.0% $0.54 $2.6B 12.8% $0.48 3Q25 3Q26 3Q25 3Q26 3Q25 3Q26 Y/Y change (USD): +5% 120 bps 13% 11
Slide 12: 9M 2026 IFRS results
9M 2026 IFRS results Worldwide net sales Operating margin Diluted EPS 13.7% $8.2B $7.6B $1.53 8.4% $0.92 9M25 9M26 9M25 9M26 9M25 9M26 Y/Y change (USD): +7% -530 bps1 -40%1 1. 9M26 included a pre-tax, non-cash net charge of $402 million related to the discontinuation of the IOL programs acquired fro
Slide 13: Q3 2026 IFRS operating margin bridge
Q3 2026 IFRS operating margin bridge 3Q26 vs. 3Q25, % of net sales 3.4 — (0.7) (1.5) 14.0 0.0 14.0 12.8 3Q25 Gross SG&A R&D Other income/ Foreign 3Q26 Margin1 expense 2 Exchange 1. 3Q26 included tariff refunds, lower amortization and manufacturing efficiencies, partially offset by a charge for fair
Slide 14: 9M 2026 IFRS operating margin bridge
9M 2026 IFRS operating margin bridge 9M26 vs. 9M25, % of net sales 3.3 (0.5) 13.7 (5.0) 8.1 0.3 8.4 (3.4) 9M25 Gross SG&A R&D2 Other income/ Foreign 9M26 Margin1 expense 3 Exchange 1. 9M26 included tariff refunds and lower amortization. 2. 9M26 included included a pre-tax, non-cash net charge of $40
Slide 15: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 15
Slide 16: Q3 2026 Core results
Q3 2026 Core results1 Worldwide net sales Core operating margin Core diluted EPS $2.7B $0.91 $2.6B 21.8% 20.2% $0.79 3Q25 3Q26 3Q25 3Q26 3Q25 3Q26 Y/Y change (cc): +5% +150 bps +15% 1. Core operating margin, core diluted EPS, and constant currency growth, including FX impacts, are non-IFRS measures.
Slide 17: 9M 2026 Core results
9M 2026 Core results1 Worldwide net sales Core operating margin Core diluted EPS 21.2% $2.60 $8.2B 20.0% $7.6B $2.29 9M25 9M26 9M25 9M26 9M25 9M26 Y/Y change (cc): +6% +110 bps +11% 17 1. Core operating margin, core diluted EPS, and constant currency growth, including FX impacts, are non-IFRS measur
Slide 18: Q3 2026 Core operating margin bridge
Q3 2026 Core operating margin1 bridge 3Q26 vs. 3Q25, % of net sales 2.8 0.1 0.1 21.7 21.8 20.2 (0.8) (0.6) 3Q25 Gross Margin SG&A R&D Other income/ Foreign 3Q26 expense Exchange Key drivers • The current year period included tariff refunds and manufacturing efficiencies, partially offset by increase
Slide 19: 9M 2026 Core operating margin bridge
9M 2026 Core operating margin1 bridge 9M26 vs. 9M25, % of net sales 1.6 0.0 21.1 0.1 21.2 (0.4) (0.1) 20.0 9M25 Gross Margin SG&A R&D Other income/ Foreign 9M26 expense Exchange Key drivers • The current year period included tariff refunds, manufacturing efficiencies and price increases, partially o
Slide 20: 9M 2026 Cash flow and balance sheet highlights
9M 2026 Cash flow and balance sheet highlights Cash and cash equivalents $1.7 billion 9M26 cash flows from operations $1.7 billion 9M26 free cash flow1 $1.3 billion Capex $344 million Debt $4.8 billion No financial covenants Returns to shareholders $748 million Including share repurchases and divide
Slide 21: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 21
Slide 22: FY 2026 Outlook
FY 2026 Outlook 2026 outlook as of August as of November Comments Net sales growth vs. prior year (cc)1 +5% to +7% +~6% Tightened (non-IFRS measure) Core operating margin1 change vs. prior year (cc)1 +90 to +190 bps +100 to +150 bps Tightened range (non-IFRS measure) Core diluted EPS1 growth vs. pri
Slide 23: Appendix
Appendix 23
Slide 24: Non-IFRS measures as defined by the Company
Appendix: Non-IFRS measures as defined by the Company Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currencies and free cash flow. Because of their
Slide 25: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Three months ended September 30, 2026 Amortization of Acquisition and Core results IFRS certain intangible integration Efficiency Other (non-IFRS ($ millions except earnings per share) results assets(1) related items(5) measures(6) it
Slide 26: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Three months ended September 30, 2025 Amortization of Acquisition and Core results IFRS certain intangible integration Other (non-IFRS ($ millions except earnings per share) results assets(1) Impairments(3) related items(5) items(9) m
Slide 27: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Nine months ended September 30, 2026 Amortization of Discontinuation of Acquisition and Core results IFRS certain intangible the PowerVision integration Efficiency Other (non-IFRS ($ millions except earnings per share) results assets(
Slide 28: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Nine months ended September 30, 2025 Amortization of Gains on certain investments in Acquisition and Core results IFRS intangible associated integration Legal Product Other (non-IFRS ($ millions except earnings per share) results asse
Slide 29: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Explanatory footnotes to IFRS to core reconciliation tables (1) Includes amortization for all intangible assets other than software. (2) For the nine months ended September 30, 2026, includes a post-tax, non-cash net charge of approxi
Slide 30: Reconciliation of free cash flow
Reconciliation of free cash flow (non-IFRS measure) The following is a summary of free cash flow for the nine months ended September 30, 2026 and 2025, together with a reconciliation to net cash flows from operating activities, the most directly comparable IFRS measure: ($ millions) 2026 2025 Net ca
Slide 31: Alcon
Alcon SEE BRILLIANTLY